Anticancer Potential of Albumin Bound Wnt/β-Catenin Pathway Inhibitor Niclosamide in Breast Cancer Cells

Basit Öğe Kaydı
dc.authorscopusidMerve Erkısa / 57126208900
dc.authorscopusidEngin Ulukaya / 6602927353
dc.authorwosidMerve Erkısa / AAM-1001-2020
dc.authorwosidEngin Ulukaya / KYY-4020-2024
dc.contributor.authorArı, Ferda
dc.contributor.authorErkısa, Merve
dc.contributor.authorPekel, Gonca
dc.contributor.authorErtürk, Elif
dc.contributor.authorBüyükkoroğlu, Gülay
dc.contributor.authorUlukaya, Engin
dc.date.accessioned2025-04-18T09:59:36Z
dc.date.available2025-04-18T09:59:36Z
dc.date.issued2021
dc.departmentİstinye Üniversitesi, Rektörlük, Uygulama ve Araştırma Merkezleri, Moleküler Kanser Uygulama ve Araştırma Merkezi
dc.description.abstractAlbumin-based nanoparticle transport systems (nab-technology) are a new strategy in cancer treatment and we aimed to increase the effectiveness of Niclosamide using this technology. Niclosamide was bound with bovine serum albumin (BSA) by desolvation to yield nanoparticle albumin-bound Niclosamide (nab-Niclo). Nab-Niclo anticancer activity was assessed by proliferation, apoptosis and DNA damage analyses on breast cancer cells. The results implied that nab-Niclo was a more potent agent in the inhibition of cell viability than free Niclosamide and albumin. Flow cytometry analysis show that nab-Niclo triggered apoptosis by caspase and mitochondria-dependent pathways in cells and nab-Niclo enhances apoptosis by induce DNA damage in cells. Overall results of this study showed that the nanoparticle form of Niclosamide is effective for breast cancer treatment, presenting a new treatment strategy that can be safe and effective for breast cancer patients. © 2021 Wiley-VCH GmbH.
dc.description.sponsorshipThe language proofreading has been made by Marguerite Dreyer who is a native speaker and working for the Foreign Language Department at Istinye University as marked red in manuscript. We thank her a lot.
dc.identifier.citationAri, F., Erkisa, M., Pekel, G., Erturk, E., Buyukkoroglu, G., & Ulukaya, E. (2021). Anticancer potential of albumin bound Wnt/β‐catenin pathway inhibitor niclosamide in breast cancer cells. ChemistrySelect, 6(29), 7463-7475.
dc.identifier.doi10.1002/slct.202100819
dc.identifier.endpage7475
dc.identifier.issn23656549
dc.identifier.issue29
dc.identifier.scopus2-s2.0-85153297664
dc.identifier.scopusqualityQ3
dc.identifier.startpage7463
dc.identifier.urihttp://dx.doi.org/10.1002/slct.202100819
dc.identifier.urihttps://hdl.handle.net/20.500.12713/6909
dc.identifier.volume6
dc.identifier.wosWOS:000765993600005
dc.identifier.wosqualityQ3
dc.indekslendigikaynakScopus
dc.indekslendigikaynakWeb of Science
dc.institutionauthorErkısa, Merve
dc.institutionauthorUlukaya, Engin
dc.institutionauthoridMerve Erkısa / 0000-0002-3127-742X
dc.institutionauthoridEngin Ulukaya / 0000-0003-4875-5472
dc.language.isoen
dc.publisherJohn Wiley and Sons Inc
dc.relation.ispartofChemistrySelect
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectAlbumin
dc.subjectApoptosis
dc.subjectBreast Cancer
dc.subjectNanoparticles
dc.subjectNiclosamide
dc.titleAnticancer Potential of Albumin Bound Wnt/β-Catenin Pathway Inhibitor Niclosamide in Breast Cancer Cells
dc.typeArticle

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Moleküler Kanser Uygulama ve Araştırma Merkezi Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu